PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1659617-3 1991 The mechanisms underlying diminished plasma corticotropin (ACTH) responses to arecoline may differ in patients with autonomic failure. Arecoline 78-87 proopiomelanocortin Homo sapiens 59-63 6289276-2 1982 Notably, in humans, intravenous infusion of centrally active cholinomimetic drugs, such as physostigmine or arecoline, may produce significant increases in plasma concentrations of prolactin and beta-endorphin immunoreactivity. Arecoline 108-117 proopiomelanocortin Homo sapiens 195-209 6289276-3 1982 In three separate studies, conducted collaboratively between the National Institute of Mental Health and the University of California at San Diego, physostigmine and arecoline associated increases in plasma concentrations of beta-endorphin immunoreactivity were highly correlated with increases in plasma prolactin concentrations. Arecoline 166-175 proopiomelanocortin Homo sapiens 225-239 7797620-3 1995 We investigated the effect of a muscarinic cholinergic agonist, arecoline, which stimulates the secretion of corticotropin-releasing hormone (CRF) and adrenocorticotropic hormone (ACTH) on the immune system. Arecoline 64-73 proopiomelanocortin Homo sapiens 151-178 7797620-3 1995 We investigated the effect of a muscarinic cholinergic agonist, arecoline, which stimulates the secretion of corticotropin-releasing hormone (CRF) and adrenocorticotropic hormone (ACTH) on the immune system. Arecoline 64-73 proopiomelanocortin Homo sapiens 180-184 8584603-8 1995 Acute arecoline administered to 14 subjects produced unpleasant side-effects (e.g. nausea, vomiting), mean adrenocorticotrophic hormone (p = .0006), cortisol (p = .0001) and beta-endorphin (p = .0001) levels were elevated. Arecoline 6-15 proopiomelanocortin Homo sapiens 174-188